Diversity is literally built into our DNA. Mutation, recombination, and non-assortative mating have all contributed to the wonderful explosion in human variation we witness today. Though humans largely share a common genetic blueprint, they also exhibit marvelous diversity in phenotype, including susceptibility to disease. It is foolish to ignore the full catalog of human genetic variation. The larger the lens, the wider the swath of biology we can capture; the longer the generation tree, the more time for mutations to occur; the broader the geography, the greater the opportunity for genetic drift and natural selection. These truths enable investigators to leverage such differences for discovery, fine-mapping, and understanding health disparities. Genetic discovery in a specific ethnic group has the potential to benefit everyone. A variant that increases disease susceptibility in one group not only has public health implications for that group, but it may also point to a novel molecular pathway whose perturbation may confer a benefit whether the recipient carries the variant or not: statins benefit not only those with familiar hypercholesterolemia mutations, and a drug developed from genetic discovery in Latinos may be useful for those of African, European, or Asian descent. It is therefore time to break down the barriers that constrain global discovery. With due attention to privacy concerns, with the ethical imperative to avoid exploitation, and with the appropriate incorporation of cultural sensitivities, we should embrace the notion that our DNA is the common patrimony of all humankind, and the diversity within it enriches us all.
Toward Global Genomics

Eleftheria Zeggini
Wellcome Sanger Institute
In recent years, the field of human genetics has witnessed great success in identifying complex disease risk variants, but the vast majority of studies to date have focused on cosmopolitan populations, primarily of European descent. The study of diverse populations presents exciting opportunities in understanding disease processes and accelerating the path to translation globally-for example, through the discovery of novel loci, fine-mapping of established signals, and a better definition of the complex interplay between genetic and environmental factors in a population-specific context. Several design and methodology challenges remain in order to realize this aspiration. Wholegenome sequencing efforts are required to provide insights into the genomic architecture of less-well-studied populations, boosting their representation on global reference panels and improving our understanding of their population genetics characteristics to enable powerful study design. Large-scale, deeply-phenotyped cohorts spanning a range of different populations and designed for the study of genetics and genomics are needed; and methodological advances in leveraging information across heterogeneous strata will be necessary to ensure powerful data integration. The tools required to study diverse populations are now emerging and the field is increasingly embracing the exciting prospect of inclusive, worldwide collaborations paving the path to truly global human genomics research.
Remember Africa
Michè le Ramsay
University of the Witwatersrand
It is at our peril that we restrict human genetics and genomics research to populations in well-resourced countries. The reasons are essentially 3-fold. First, the greatest genetic diversity is present in many of the under-represented populations of the world, including those in Africa, Oceania, and the Americas. Second, there are unique gene-environment interactions that can tell us much about the biology of disease and disease susceptibility. Lastly, understanding how the past has shaped today's populations provides clues to survival potential during periods of dramatic change, including climatic fluctuations and access to resources. In low-resourced environments, we battle competing priorities for the advancement of health with poverty, famine, corruption, political instability, and war. My area of interest is Africa. To promote human genetics and genomics research in Africa, we need to advocate more strongly to swing political will toward sustainable funding for genomics research in the broader field of biomedical research. We need to attract big funding and to focus on data generation and skills enhancement and retention in genomics to support initiatives like Human Heredity and Health in Africa, the African Society of Human Genetics, and the Alliance for Accelerating Excellence in Science in Africa. There is ample evidence that heritable diseases are on the rise globally because of our changing environment, and Africa will not be spared premature mortality and increased health burden. Critical to improved health will be an understanding of regional and sex-specific differences in gene-environment interactions that turn the key to childhood and adult multimorbidity in the 21 st Century.
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Increasing Coverage
Xun Xu
Beijing Genomics Institute Genetic research and disease treatments are being misled by the data of well-studied populations such as Caucasians, creating an emerging problem for many underrepresented populations. For example, BRCA genes contain many Chinese populationspecific VUS (variants of uncertain/unknown significance) with substantially different clinical outcomes. The only way to address this disparity is to understand the genetic diversity of all of us. The 1000 Genomes Project is one of the best examples of such efforts, in which many previously underrepresented populations were sequenced, providing higher resolution for mapping of diseasecausing variants, better understanding of human demography, and more accurate interpretation of pathogenicity in specific populations. However, the 1000 Genomes Project was just a start. Many populations are still underrepresented or completely unrepresented. Large and diverse groups such as the Chinese population may need 1 million individuals sequenced to accurately represent their diversity. Due to the significant reduction in sequencing cost, funding will not be the major challenge. Instead, legal, ethical, privacy, and data-sharing issues may result in bottlenecks of sample collection and data sharing. However, due to the significant benefits of genetic datasets of underrepresented populations, both academic and industry researchers must push to solve these challenges. Policy makers have been or will be facilitating the generation of such datasets by supporting projects like precision medicine initiatives in many countries. In the meantime, self-reporting datasets with block-chain technologies could be another interesting alternative to accelerate the generation of genetic datasets for underrepresented populations.
Sounding the Call Lucia A. Hindorff
Division of Genomic Medicine, National Human Genome Research Institute
The call to increase diversity in biomedical research has recently been sounded from multiple vantage points, highlighting shortcomings in how diversity is reflected in designing, funding, and publishing biomedical research. Greater inclusion of diverse populations, such as racial or ethnic minorities or the medically underserved, yields ethical and scientific benefits. One underappreciated aspect is that missed opportunities from ignoring diversity produce an information disparity that widens as bias at the discovery stage of research propagates to translational and implementation stages. For example, allele frequencies from diverse populations are not well represented in public databases. Though improving, the association of this insufficiency with increased potential for clinical misdiagnoses is disquieting. The evidence base for implementation needs to incorporate diversity with the same robustness emphasized for other aspects of study design. Developing this evidence base calls for effort from each of us. Scientists recognize the importance of diversity but may be dissuaded by funding constraints and pragmatic challenges to engaging underrepresented populations. But those times are changing as funders commit to increasing diversity and participantcentered efforts gain momentum. Opportunities to enhance diversity in biomedical research have never been greater. Where we have the privilege of supporting research to improve health for all of us, let us continue the conversation.
Failures of Representation
Timothy Thornton
University of Washington
There have been significant efforts in recent years to develop resources incorporating genetic discoveries of human traits/outcomes from genome-wide association studies (GWAS) into precision or personalized medicine. The vast majority of genetic discoveries through GWAS, however, have been identified in populations of European ancestry, and there continues to be systematic underrepresentation of participants from diverse populations in human genetics research. For example, from 2009 to 2016, the percentage of genetic research participants with non-European ancestry included in NIH-supported research increased only marginally, from 4% to 6%, despite the NIH Revitalization Act mandated by Congress requiring underrepresented minority (URM) participants be included in clinical and biomedical research. The dearth of healthrelated genetic studies in URM populations is particularly alarming as these populations have disproportionate burdens of morbidity and mortality. Recent work has shown that existing ''risk'' loci identified in European populations are consistently biased and are generally not transferable to other populations. Indeed, polygenic risk scores based on genetic variants identified in studies of European populations have been shown to not only give biased risk scores, but also directional inconsistencies in other populations. There is great potential that increasing diversity in medical genomics will lead to novel genetic discoveries that will be beneficial to all populations. However, failing to significantly increase the number of genetic studies in diverse, non-European ancestry populations continues to have significant ramifications, and will be at the peril of exacerbating health disparities.
The Path Forward
Nanibaa' A. Garrison
University of Washington
Many people from diverse backgrounds are underrepresented in genetic research. I am hoping to change that through community engaged research, developing guidelines, and helping to create policies for communities to feel assured that their interests are protected. My vision is to promote equity in genomics research by creating ways for Indigenous people and researchers to work together, by collaboratively developing ethical research practices and honoring community interests. Striving for equity in health can be challenging but is not impossible. To start, researchers should aim to identify creative ways to communicate with underrepresented communities. This might take the form of community engagement and outreach activities; it could also include using culturally relevant examples or metaphors to describe concepts or even creating new language such that members of the community can understand research goals and procedures. Having an interdisciplinary team that includes members of underrepresented populations helps to create an atmosphere of trust and mutual respect, and this can help to garner support from both the research side and the community side. Including team members from the community allows for them to act as cultural navigators to ensure a respectful engagement process. Recently, I worked with the Summer Internship for INdigenous peoples in Genomics (SING) Consortium to develop a framework to guide researchers in promoting ethical engagement with Indigenous communities, particularly for genetic research. While we propose six key considerations for respectful engagement, we recognize that a lot more work needs to be done to realize our vision for inclusion and equity.
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